Soleus Capital Management L.P. Sells 49,500 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Soleus Capital Management L.P. cut its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 52.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,500 shares of the company’s stock after selling 49,500 shares during the period. Soleus Capital Management L.P.’s holdings in Viridian Therapeutics were worth $872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. R Squared Ltd acquired a new position in Viridian Therapeutics during the fourth quarter worth approximately $26,000. Foresite Capital Management VI LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $38,000. AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company’s stock worth $147,000 after acquiring an additional 1,516 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Viridian Therapeutics in the 4th quarter valued at $164,000.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. JMP Securities decreased their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Needham & Company LLC cut their price objective on shares of Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Royal Bank of Canada decreased their target price on Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 7th. Finally, The Goldman Sachs Group dropped their price target on Viridian Therapeutics from $31.00 to $27.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.70.

Viridian Therapeutics Stock Up 2.5%

NASDAQ VRDN opened at $12.94 on Monday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -3.00 and a beta of 0.57. The company has a 50 day moving average of $13.41 and a 200-day moving average of $17.10. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Viridian Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities research analysts expect that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.